PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 9 | 1 | 28-33
Article title

Intervention for cardiovascular risk factors decreases adipocyte fatty acid-binding protein levels in males - a pilot study

Content
Title variants
Languages of publication
EN
Abstracts
EN
Cardiovascular disease (CVD) remains the leading cause of mortality in developed countries. According to the 2012 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice, family history is a cornerstone for risk stratification of CVD. First-degree relatives are persons in whom CVD should be assessed and targeted intervention should be performed. The aims of this pilot study were (i) to determine risk factors (RFs) for cardiovascular disease (CVD) in a group of first-degree relatives of patients with CVD at baseline and after 1 year, (ii) to measure adipocyte fatty acid-binding protein (A-FABP) levels as a potential connecting link between metabolic disease and atherosclerosis, and (iii) to determine the impact of targeted intervention on these parameters. The study comprised 62 asymptomatic subjects (41 males; mean age of 53.8±8.3 years). Preventive examinations and interventions were carried out at baseline and at 1-year follow-up to assess RFs and evaluate A-FABP levels. At 1 year, males had significantly lower levels of cholesterol (median 5.18 vs 4.67, p=0.005), HDL (median 1.24 vs 1.14, p=0.021), LDL (median 3.08 vs 2.46, p=0.021), ApoB (median 0.99 vs 0.82, p=0.012) and A-FABP (median 19.84 vs 16.73, p = 0.015). In females after 1 year, only significantly lower levels of fibrinogen (median 3.10 vs 2.79, p=0.043) were found. All subjects were clinically examined or contacted by phone after a mean of 36.7 months (range, 11–55). Over that time, no serious complications were noted. In males, intervention for RFs leads to lower levels of A-FABP as a potential RF linking metabolic syndrome to atherosclerosis.
Publisher

Journal
Year
Volume
9
Issue
1
Pages
28-33
Physical description
Dates
published
1 - 2 - 2014
online
4 - 2 - 2014
Contributors
author
  • Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
author
  • Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
author
  • Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Department of Preventive Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
author
  • Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Department of Exercise Medicine and Cardiovascular Rehabilitation, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
  • Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, Olomouc, 779 00, tr. Svobody 8
References
  • [1] De Backer G., Ambrosionie E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). http://www.escardio.org/guidelines-surveys/escguidelines/GuidelinesDocuments/guidelines-CVDprevention.pdf. 14.3.2013
  • [2] Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al., European guidelines on cardiovascular disease prevention in clinical practice: executive summary, EJCPR., 2007, 14, 1–113
  • [3] Kazemi M.R., McDonald C.M., Shigenaga J.K., Grunfeld C., Feingold K.R., Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1220–1224 http://dx.doi.org/10.1161/01.ATV.0000159163.52632.1b[Crossref]
  • [4] Erbay E., Cao H., Hotamisligil G.S. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome, Curr. Atheroscler. Rep., 2007, 9, 222–9. http://dx.doi.org/10.1007/s11883-007-0023-6[Crossref]
  • [5] Lam D.C., Xu A., Lam K.S. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance, Eur. Respir. J., 2009, 33, 346–351 http://dx.doi.org/10.1183/09031936.50075408[Crossref][WoS]
  • [6] Tuncman G., Erbay E., Hom X., De Vivo I., Campos H., Rimm E.B., et al., A genetic variant at the fatty acid binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease, Proc. Natl. Acad. Sci. USA., 2005, 103, 6970–6975 http://dx.doi.org/10.1073/pnas.0602178103
  • [7] Tso A.W.K., Xu A., Sham P.C., Wat N.M.S, Wang Y, Fong C.H.Y., et al., Serum adipocyte fatty acidbinding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort, Diabetes Care., 2007, 30, 2667–2672 http://dx.doi.org/10.2337/dc07-0413[Crossref][WoS]
  • [8] Miyoshi T., Onoue G., Hirohata A., Hirohata S., Usui S., Hina K., et al., Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound, Atherosclerosis, 2010, 211, 164–169 http://dx.doi.org/10.1016/j.atherosclerosis.2010.01.032[Crossref][WoS]
  • [9] Rhee E.J., Lee W.Y., Park CY. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults, Eur. J. Endocrinol., 2009, 160, 165–172 http://dx.doi.org/10.1530/EJE-08-0665[Crossref][WoS]
  • [10] Krusinova E., Pelikanova T., Fatty acid binding proteins in adipose tissue: A promising link between metabolic syndrome and atherosclerosis?, Diabetes Research and Clinical Practice, 2008, 82, 127–134 http://dx.doi.org/10.1016/j.diabres.2008.09.023[Crossref]
  • [11] Stejskal D., Karpíšek M., Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?, Eur. J. Clin. Invest., 2006, 36, 621–625 http://dx.doi.org/10.1111/j.1365-2362.2006.01696.x[Crossref]
  • [12] Karpisek M., Stejskal D., Kotolova H., Kollar P., Janoutova G., Ochmanova R., et al., Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidemia, Eur. J. Clin. Invest., 2007, 37, 637–642 http://dx.doi.org/10.1111/j.1365-2362.2007.01835.x[WoS][Crossref]
  • [13] Makowski L., Brittingham K.C., Reynolds J.M., Sutles J., Hotamisligil G.S., The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities, J. Biol. Chem., 2005, 280, 12888–12895 http://dx.doi.org/10.1074/jbc.M413788200[Crossref]
  • [14] Peeters W., de Kleijn D.P.V, Vink A., de Weg S., Schoneveld A.H., Ste S.K, et al., Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events, Eur. Heart J., 2011, 32, 1758–1768 http://dx.doi.org/10.1093/eurheartj/ehq387[WoS][Crossref]
  • [15] Doi M., Miyoshi T., Hirohata S., Nakamura K., Usui S., Takeda K, et al., Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men, Cardiovasc. Diabetol., 2011, 10, 44 http://dx.doi.org/10.1186/1475-2840-10-44[WoS]
  • [16] Sovova E., Vrbkova J., Stejskal D., Kaletova M., Kaminek M., Metelkova I., Sova M., Benusova I., Doupalova P., Is there dependence between the level of adipocyte fatty acid-binding protein and calcium score in asymptomatic relatives of patients with cardiovascular diseases?, Vnitrni lekarstvi, 2013, 59(1), 31–36
  • [17] Mosca L., Mochari H., Liao M., Christian A.H., Edelman D.J., Aggarwal B., et al., A novel family-based intervention trial to improve heart health: FIT Heart: results of a randomized controlled trial, Circ. Cardiovasc. Qual. Outcomes, 2008, 1, 98–106 http://dx.doi.org/10.1161/CIRCOUTCOMES.108.825786[Crossref]
  • [18] Naslindh-Ylispangar A., Sihvonen M., Sarna S., Vanhanen H., Kekki P., Has brief counseling an impact on the risk factors for cardiovascular disease in 40-year-old me. A three year follow-up study, Cent. Eur. J. Med., 2008, 3, 300–307 http://dx.doi.org/10.2478/s11536-008-0034-x[Crossref][WoS]
  • [19] Bertuzzi M., Negri E., Tavani A., La Vecchia C., Family history of ischemic heart disease and risk of acute myocardial infarction, Prev. Med., 2003, 37, 183–187 http://dx.doi.org/10.1016/S0091-7435(03)00094-X[Crossref]
  • [20] Janssens A.C., Wilde A.A., van Langen I.M., The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease, Neth. Heart. J., 2011, 19, 85–88 http://dx.doi.org/10.1007/s12471-010-0069-x[Crossref][WoS]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0231-0
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.